Henry Ford Health

Henry Ford Health Scholarly Commons
Urology Articles

Urology

9-19-2022

Time to second biochemical recurrence as a prognostic indicator
in postprostatectomy patients who undergo salvage radiation
therapy: An RTOG 9601 based post hoc analysis
Emily C. Brodowsky
Akshay Sood
Mohit Butaney
Sami E. Majdalani
Alex Stephens

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/urology_articles

Authors
Emily C. Brodowsky, Akshay Sood, Mohit Butaney, Sami E. Majdalani, Alex Stephens, Nicholas Corsi,
Austin J. Piontkowski, Ivan Rakic, Marcus Jamil, Deepansh Dalela, James O. Peabody, Craig G. Rogers,
and Firas Abdollah

|

Accepted: 22 August 2022

DOI: 10.1002/pros.24436

ORIGINAL ARTICLE

Time to second biochemical recurrence as a prognostic
indicator in postprostatectomy patients who undergo salvage
radiation therapy: An RTOG 9601 based post hoc analysis
Emily Chan Brodowsky MD1,2 | Akshay Sood MD1,2,3 | Mohit Butaney MD1
Sami E. Majdalany MD1 | Alex Stephens MS1 | Nicholas Corsi BS4 |
Austin J. Piontkowski BS4 | Ivan Rakic BS4 | Marcus Jamil MD1,2 |
Deepansh Dalela MD1,2 | James O. Peabody MD1,2 | Craig G. Rogers MD1,2
Firas Abdollah MD

|

|

1,2

1

Department of Urology, VCORE—Vattikuti
Urology Institute Center for Outcomes
Research, Analytics and Evaluation, Henry
Ford Hospital, Detroit, Michigan, USA

2

Department of Urology, Vattikuti Urology
Institute, Henry Ford Hospital, Detroit,
Michigan, USA
3

Department of Urology, University of Texas
MD Anderson Cancer Center, Houston,
Texas, USA
4

Division of Medicine, School of Medicine,
Wayne State University, Detroit,
Michigan, USA

Abstract
Introduction and Objective: The prognostic significance of a “second” biochemical
recurrence (sBCR) after salvage radiation therapy (sRT) with/without hormonal
therapy following primary radical prostatectomy in men with prostate cancer has not
been examined. We hypothesized that a shorter time to sBCR will be associated with
worse cancer control outcomes.
Methods: The RTOG 9601 study included 760 patients with tumor stage pT2/T3,
pN0, who had either persistently elevated prostate‐specific antigen (PSA) postradical
prostatectomy or developed subsequent biochemical recurrence with PSA levels
between 0.2 and 4.0 ng/ml. All patients received sRT (with or without 2 years of
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Bicalutamide) from 1998 to 2015. For our study, we focused on 421 patients who
had sBCR after sRT—which was defined as a PSA increase of at least 0.3 ng/ml over
the first nadir. Patients were divided into two categories: early sBCR (n = 210) and
late sBCR (n = 211) using median time to sBCR (3.51 years). All patients who
experienced sBCR received salvage hormonal therapy. Competing‐risk analysis was
used to examine the impact of early versus late sBCR on prostate cancer specific
mortality (CSM), after accounting for available covariates.
Results: The majority of patients were age 60 years or older (75.8%), had pT3 disease
(74.8%), and Gleason score 7 (75.2%). Overall, 13.8% had persistent PSA initially
after surgery. At 10 years, starting at the time of sBCR, CSM rate was 31.3% in the
early sBCR group versus 20.0% in the late sBCR group. In competing‐risk analysis,
time to sBCR was an independent predictor of CSM, where patients with early sBCR
had 1.7‐fold higher CSM risk (p = 0.026) than their counterparts with late sBCR.
Conclusions: Time to sBCR after sRT (with or without concomitant Bicalutamide) is a
significant predictor of CSM following initial radical prostatectomy. This information
can be used to guide subsequent treatments, and to counsel patients.
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| INTRODUCTION

primary BCR, defined as postsurgery PSA >0.2 ng/ml. The patients
were randomized if they satisfied the following inclusion criteria:

Prostate cancer (PCa) is the leading cause of cancer for the American

Karnofsky Performance Score ≥80, negative bone and CT scans, no

male, accounting for 26% of cancer diagnoses.1 While the majority of

previous chemotherapy or radiation therapy for PCa, and no previous

patients present with low‐intermediate risk disease at diagnosis, the

hormone therapy other than short‐term neoadjuvant hormonal

main bulk of mortality is derived from those presenting with

therapy. At randomization, patients were either assigned to sRT with

2

advanced or metastatic disease.

Many patients with advanced

Bicalutamide 150 mg daily, or sRT with placebo. sRT was started

disease end‐up needing multimodal treatment, which usually consists

within 12 weeks after randomization with a total dose of 64.8 Gy to

of radical prostatectomy followed by radiation therapy and/or

the prostatic fossa. Patients were assessed by history, physical exam,

hormonal therapy upon biochemical recurrence (BCR). The latter is

and biochemical tests before and after sRT. Subsequent follow‐up

defined by the AUA as a prostate‐specific antigen (PSA) level of

evaluation occurred every 3 months for 2 years, then every 6 months

0.2 ng/ml or higher on two consecutive measurements.3 While most

for 3 years, and then yearly. This study was aimed at comparing

patients have a good initial response to such a treatment, around

outcomes of patients with early time to “second” biochemical

44%–67.9% of these individuals develop a second BCR after radical

recurrence (sBCR) and late time to sBCR, thus, patients who did not

prostatectomy and salvage radiation therapy (sRT).4

develop sBCR were excluded from the study.

Several reports have addressed the role of the initial or primary

Following sRT, a second BCR that was defined as a PSA

BCR after radical prostatectomy as a prognostic variable, and it has

increase of at least 0.3 ng/ml above the nadir after protocol

been shown to correlate with different cancer control outcomes.5 On

treatment or at the initiation of any subsequent hormone therapy,

the other hand, there is scarcity of data addressing the meaning or

prompted imaging studies.4 If metastatic disease was noted or if

the role of a second BCR after sRT in patients treated initially with

the PSA level reached above 4.0 ng/ml, then maximum androgen

radical prostatectomy. This information might play a key role in

blockade was recommended.

stratifying patients with advanced disease based on their progression
risk, which might improve patient counseling and the individualization
of treatment. To address this gap in knowledge, we tested the

2.3 |

Covariates

hypothesis that a second BCR in the setting of patients who fails
radical prostatectomy with subsequent sRT is a predictor of PCa

In the current study, covariates were categorized as reported in the

specific mortality. Our cohort consisted of patients who were

original trial,4 and consisted of patient age, race, Karnofsky

included in the RTOG 9601 study.

Performance Score, pathological tumor stage, Gleason score, surgical
margin status, neo‐adjuvant hormone use before radical prostatectomy, time from surgery to first BCR, pre‐sRT PSA level (<0.7 ng/ml,

2

| MATERIALS AND METHODS

0.7–1.5 ng/ml, 1.5–4.0 ng/ml), and hormonal treatment status with
sRT (24 months of Bicalutamide vs. 24 months of placebo). Finally,

2.1

| Data acquisition

the time from randomization to second BCR, was used as main
predictor variable. The median time to second BCR was used to

The NCI manages a centralized, controlled‐access database (National

divide patients into two categories. The “early sBCR” group included

Clinical Trials Network [NCTN]/NCORP Data Archive) to store and

patients who were found to have their sBCR earlier than or equal to

share datasets generated from clinical trials of the NCTN. Using this

the median time to second BCR versus the “late sBCR” group

framework, we requested and obtained clinical trial data to perform

included patients who were found to have their sBCR later than the

secondary analysis on the impact of second BCR on cancer specific

median time to second BCR.

mortality (CSM) in patients who underwent radical prostatectomy
and subsequent sRT.

2.4 |
2.2

| Study population

Endpoints

The primary outcome of interest was PCa‐specific mortality. Disease‐
specific death included all deaths from PCa or treatment complica-

A detailed description of the Radiation Therapy Oncology Group

tions as well as death from an unknown process in patients with

(RTOG) 9601 trial cohort, which was sponsored by the NCI, has been

active PCa, on the basis of centrally reviewed cause of death.4

4

previously published. Briefly, the trial recruited PCa patients with pT2‐

This was tracked continuously as long as patients maintained follow

pT3, N0 disease, who underwent radical prostatectomy and developed

up for the duration of the study.
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T A B L E 1 Descriptive characteristics
of the 421 patients found to have a
second BCR after radiation therapy with
concurrent salvage hormonal therapy with
bicalutamide postradical prostatectomy

Patient characteristics

Overall n (%)

Early sBCR n (%)

Late sBCR n (%)

421 (100)

210 (100)

211 (100)

3

p value

Age group (years)
≤59

102 (24.23)

51 (24.29)

51 (24.17)

60–69

228 (54.16)

120 (57.14)

108 (51.18)

91 (21.62)

39 (18.57)

52 (24.64)

≥70

0.2885

Gleason score
<2

1 (0.24)

2–6

103 (24.47)

39 (18.57)

64 (30.33)

7

237 (56.29)

119 (56.67)

118 (55.92)

52 (24.76)

28 (13.27)

8–10

80 (19)

0 (0)

1 (0.47)

0.0013

Pathologic tumor stage
pT2

106 (25.18)

44 (20.95)

62 (29.38)

pT3

315 (74.82)

166 (79.05)

149 (70.62)

<0.7

200 (47.51)

80 (38.1)

120 (56.87)

0.7–1.5

140 (33.25)

80 (38.1)

60 (28.44)

81 (19.24)

50 (23.81)

31 (14.69)

<0.5

363 (86.22)

178 (84.76)

185 (87.68)

≥0.5

58 (13.78)

32 (15.24)

26 (12.32)

376 (89.31)

191 (90.95)

185 (87.68)

African American

35 (8.31)

15 (7.14)

20 (9.48)

Other

10 (2.38)

4 (1.9)

6 (2.84)

≤90

103 (24.47)

58 (27.62)

45 (21.33)

100

318 (75.53)

152 (72.38)

166 (78.67)

Negative

126 (29.93)

69 (32.86)

57 (27.01)

Positive

295 (70.07)

141 (67.14)

154 (72.99)

sRT + placebo

252 (59.86)

150 (71.43)

102 (48.34)

sRT + 24 mo Bicalutamide

169 (40.14)

60 (28.57)

109 (51.66)

0.0463

PSA at entry (ng/ml)

>1.5

0.0005

PSA Nadir (ng/ml)
0.3854

Race group
Caucasian

0.5467

Karnofsky score
0.1332

Surgical margins
0.1905

Therapy group
<0.0001

Abbreviation: BCR, biochemical recurrence.

2.5

| Statistical analyses

Functions were used to depict cancer specific survival estimates
at different time points based on early versus late sBCR status.

Frequencies and proportions were reported for categorical variables,

Moreover, competing‐risks regression analysis was used to test

while median and interquartile range (IQR) were reported for

the impact of early versus later sBCR on CSM, after adjusting for

continuous variables. T tests and Chi‐square tests were used to

all available covariates. Death due to causes other than PCa was

evaluate the statistical significance of differences in continuous

classified as “other‐cause mortality” and accounted for in

and categorical variables, respectively. Cumulative Incidence

competing‐risk analysis.
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All analyses were performed using SAS 9.4 (SAS Institute, Cary,

different with 81.4% of patients in the early sBCR group at or

North Carolina). Two‐sided statistical significance was defined as a

above Gleason 7 PCa while this was only seen in 69.2% of

p value <0.05. Institutional review board approval was obtained

patients in the late sBCR group (p = 0.001). Pathologic T3 stage

before the study was conducted, in accordance with institutional

was significantly different with 79.1% of patients in the early

regulations when dealing with deidentified patient data.

sBCR group having pT3 PCa versus 70.6% of patients in the late
sBCR group (p = 0.04). PSA nadir, patient race, Karnofsky score,
and surgical margins were all comparable between the two

3

| RESULTS

groups. More patients in the late sBCR group (51.7%) were
treated with hormone therapy compared with those in the early

3.1

| Descriptive characteristics

sBCR group (28.6%) (p < 0.001).

From the original RTOG 9601 study, 421 patients were found to have a
sBCR after sRT with or without 24 months of Bicalutamide. Complete
descriptive characteristics of our patient cohort are provided in Table 1.

3.2 | Cumulative incidence and competing‐risks
regression analysis

The majority of patients were age 60 years or older (75.8%), had
pathological T3 disease (74.8%), and had a Gleason score ≥7 (75.3%).

To compare CSM between the two groups, cumulative incidence

Additionally, 86.2% of patients had a PSA nadir under 0.5 ng/ml after sRT.

functions were used. Overall, in patients who experienced a sBCR, the

Overall, 13.8% had persistent PSA initially after surgery. Overall median

5‐ and 10‐year CSM rates were 8% (95% confidence interval [CI]:

follow‐up time was 7.3 years (IQR: 4.2–9.9).

5%–11%) and 27% (95% CI: 22%–32%), respectively. When patients

The median time to sBCR in our study was 3.51 years (0–14.16

were stratified based on median time to second BCR, the 5‐ and 10‐year

years). Using this cut‐off, we identified 210 patients in our cohort

CSM rate was 11.2% and 31.3% in the early second BCR group versus

who had early sBCR (within ≤3.51 years), while the remaining 211

4.27% and 20.0% in the late second BCR group (Figure 1, p = 0.03).

patients had late BCR (>3.51 years).

The univariable observations were conferred on multivariable

When stratified by these categories, patient age was compa-

competing‐risk analysis, where time to second BCR was an

rable between the two groups, both groups having 76% of

independent predictor of prostate CSM. Specifically, patients in

patients aged 60 or older. Gleason scores were significantly

the early sBCR group had a 1.69‐fold higher CSM risk (hazard ratio

F I G U R E 1 Cumulative incidence of prostate cancer‐specific mortality in patients with early versus late time to second BCR. BCR,
biochemical recurrence [Color figure can be viewed at wileyonlinelibrary.com]
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T A B L E 2 Multivariable Cox regression evaluating the effects of the
selected variables on cancer‐specific mortality in postprostatectomy
patients who have undergone salvage radiation therapy
Prostate cancer‐specific
mortality hazard ratio (95% CI)

p value

Early second BCR

1.69 (1.06–2.69)

0.02

Late second BCR

Ref.

Age ≤59

Ref.

Age 60–69

1.7 (0.94–3.14)

0.07

Age ≥70

3.53 (1.77–7.06)

0.0004

Caucasian race

Ref.

African American race

0.67 (0.24–1.86)

0.44

Other race

0.37 (0.04–3.10)

0.36

sRT + Placebo

Ref.

sRT + Bicalutamide

1.12 (0.72–1.72)

0.62

PSA <0.7 ng/ml

1.08 (0.67–1.75)

0.74

PSA 0.7–1.5 ng/ml

Ref.

PSA >1.5 ng/ml

1.43 (0.81–2.55)

Gleason score ≤6

Ref.

Gleason score 7

1.79 (0.987–3.233)

0.06

Gleason score ≥8

3.08 (1.57–6.04)

0.001

pT stage, T2

Ref.

pT stage, T3

1.38 (0.80–2.37)

Negative surgical margins

Ref.

Positive surgical margins

1.22 (0.76–1.97)

Karnofsky score, ≤90

Ref.

Karnofsky score, 100

1.45 (0.85–2.46)

0.21

0.23

0.40

0.17

5

T A B L E 3 Multivariable Cox regression evaluating the effects of the
selected variables on cancer‐specific mortality in postprostatectomy
patients who have undergone salvage radiation therapy
Prostate cancer‐specific
mortality hazard ratio
(95% CI)

p value

Time to sBCR

0.81 (0.70–0.94)

0.006

Age ≤59

Ref

Age 60–69

1.82 (0.98–3.37)

0.057

Age ≥70

3.84 (1.88–7.83)

0.0002

Caucasian race

Ref

African American race

0.717 (0.26–2.00)

0.52

Other race

0.45 (0.05–3.91)

0.47

sRT + Placebo

Ref

sRT + Bicalutamide

1.25 (0.81–1.93)

0.32

PSA <0.7 ng/ml

1.15 (0.71–1.88)

0.57

PSA 0.7–1.5 ng/ml

Ref

PSA >1.5 ng/ml

1.39 (0.80–2.42)

Gleason score ≤6

Ref

Gleason score 7

1.76 (0.97–3.18)

0.06

Gleason score ≥8

3.00 (1.55–5.82)

0.001

pT stage, T2

Ref

pT stage, T3

1.38 (0.81–2.36)

Negative surgical margins

Ref

Positive surgical margins

1.26 (0.78–2.02)

Karnofsky score, ≤90

Ref

Karnofsky score, 100

1.46 (0.86–2.49)

0.25

0.24

0.35

0.16

Abbreviations: BCR, biochemical recurrence; CI, confidence interval.

Abbreviations: sBCR, “second” biochemical recurrence; CI, confidence
interval.

[HR]: 1.69, 95% CI: 1.07–2.69, p = 0.02) than their counterparts in

is significant when sBCR is coded as categorical and continuous

the late sBCR group (Table 2). Age ≥70 was found to be an

(Tables S1 and S2). Both analyses do not demonstrate a significant

independent predictor of CSM (HR: 3.53, 95% CI: 1.77–7.06,

interaction term between time to sBCR and treatment (categorical

p = 0.0004), as was a Gleason score between 8 and 10 (HR: 3.08,

time to sBCR Wald χ2 = 0.0527; p = 0.8184 & continuous time to

95% CI: 1.57–6.04, p = 0.001). A comparison of the model was

sBCR Wald χ2 = 2.3355; p = 0.1265). For sRT+ bicalutamide, the

performed to analyze the time to sBCR as a continuous variable

interaction term was found to be nonsignificant (HR: 1.25, 95% CI:

(Table 3).” Time to sBCR was again statistically significant

0.81–1.93, p = 0.32).

(p = 0.0079). Similarly, when coded as a continuous variable, time
to sBCR was determined to be a predictor of prostate CSM
(Table 3). Age ≥70 was found to be an independent predictor of

4 |
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CSM (HR: 3.84, 95% CI: 1.88–7.83, p = 0.0002), as was a Gleason
score between 8 and 10 (HR: 3.00, 95% CI: 1.55–5.82, p = 0.001).

The treatment and management of PCa has advanced dramatically in

The continuous code of time to sBCR had a hazard ratio of 0.81

the past few decades. The 5‐year disease‐free survival rate in

(95% CI: 0.70–0.94, p = 0.006). Thus, for each additional year to

patients post‐RP is 71.2%,6 and the 5‐year rate of freedom from BCR

sBCR, the risk of prostate CSM decreases 19%.

in patients who received RP and sRT is 87%.7 At 6.1 years, Tumati

A Type 3 Wald Chi‐Square analysis was performed to

et al.8 found that PCa‐specific survival in post‐RP patients who

determine if the interaction between time to sBCR and treatment

received sRT was 83%. However, this still leaves a significant
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percentage of patients in whom PSA levels continue to rise despite

number of patients available, this study is likely not powered to

receiving sRT and thus go on to experience a sBCR. In this

support the idea that there is an interaction term.

aforementioned cohort of patients, the prognostic significance of

By analyzing the RTOG 9601 cohort data, we aim to provide a

time to a sBCR has yet to be elucidated. To address this void in the

high level of evidence for this, as of yet, unexamined question.

data, we examined the effect of time to second BCR on CSM to

Besides being a randomized clinical trial, this is the largest cohort of

better define the characteristics of this disease in patients who are

patients that has been examined on the subject of sRT following

higher risk.

radical prostatectomy and has the longest follow‐up time. Moreover,

After adjusting for all available covariables, patients who had a
time to sBCR at or below the median of 3.51 years demonstrated a

it benefits from regular and systematic follow‐up of the patients who
are included in this study.

significantly higher rate of death related to PCa (1.67‐fold higher,

This study represents a secondary analysis of level‐one

p = 0.02) as compared with those who had a time to second BCR

evidence and as such, might be underpowered to examine

greater than the median. These results correlate with prior data

differences in CSM based on timing of sBCR. However, given that

surrounding first BCR, and sBCR which revealed that earlier time to

our results found a statistically significant difference between the

BCR is associated with increased mortality.

9,10

Additionally, previous

two examined groups, it can be argued that the available sample size

work has shown that PSA kinetics is correlated with disease specific

is probably adequate to examine our endpoint. Furthermore,

survival and that more rapid rises in PSA indicate a poorer

findings must be interpreted within the limitations of a post hoc

prognosis.11,12 Together with Gleason score, pathologic T stage,

analysis. Because comparison of time to sBCR was not a planned

and PSA, the time to second BCR provides useful information and can

covariate in the initial study design, any differences between our

be factored into the prognostic algorithm to help predict a patient's

study groups may be the result of unidentified bias.15 Furthermore,

cancer progression trajectory as well as help stratify these patients

a limitation in our study is the use of bicalutamide given its side

into risk groups.

effects, but there also remains the question of whether it is

Patients in whom treatment for PCa has failed not once but twice

equivalent to standard ADT.

can be considered part of a higher risk cohort. In these patients,
limited options remain for continued management of their disease.
Hormone therapy remains one of the options still available at this

5 |

CONCLUSIONS

stage in the disease course. Indeed, 40% of patients in our specific
study group were given Bicalutamide as part of their regimen.

Based on retrospective analysis of the RTOG 9601 clinical trial

However, the exact impact of hormonal therapy in this setting and

cohort, time to sBCR was found to be an independent predictor of

how it varies between early versus late time to second BCR warrants

CSM. These findings can serve to help characterize the nature of PCa

further investigation in the future. For example, patients with early

that has failed local treatment and will be able to aid clinicians in

time to second BCR may benefit from the early introduction of

charting disease progression and predict patient outcomes. With an

chemotherapy in their treatment regimen. Studies have shown that

understanding of sBCR, its timing, and the relation of that to CSM,

adding docetaxel to patients receiving salvage radiation and hormone

physicians can use our findings to counsel patients regarding their

13

therapy resulted in improved patient survival,

with one study

prognosis, and guide their treatment. Likewise, patients with sBCR

showing a 4‐year risk reduction of 30% in overall survival (p = 0.04)

are considered to have an advanced stage disease, and are frequently

favoring chemotherapy.14

targeted by new trials to try and improve their outcomes. In this

Typically, a sBCR represents a depletion of local therapy options

context, our findings can be used to risk‐stratify patients in future

and it may be implied that cancer progression would accelerate from

trials. Continued research on recurrent PCa will build off of this data

this point resulting in a high probability of death from PCa. However,

which will support prospective trials that examine optimal stratifica-

our results indicate that most patients who experience a sBCR will

tion of these higher risk patients.

not die as a result of their disease as the 10‐year CSM rate is
20%–31%. This should be considered when counseling and develop-
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